Literature DB >> 15364979

Nosocomial transmission of CTX-M-2 beta-lactamase-producing Acinetobacter baumannii in a neurosurgery ward.

Noriyuki Nagano1, Yukiko Nagano, Christophe Cordevant, Naohiro Shibata, Yoshichika Arakawa.   

Abstract

Three strains of cefotaxime (CTX)-resistant Acinetobacter baumannii, FM0209680, FM0300106, and FM0301433, were isolated from transtracheal aspirate cultures of three patients with probable nosocomial infections in a neurosurgery ward in Japan. The CTX MICs for these isolates were greater than 128 microg/ml but were drastically reduced in the presence of 4 microg of clavulanic acid per ml. These strains were also resistant to ceftriaxone, cefpodoxime, and aztreonam but were susceptible to ceftazidime and imipenem. The profile of resistance to various broad-spectrum beta-lactams was transferred by conjugation. Strain FM0209680 was not eradicated from case patient 1 by administration of imipenem, ceftazidime, and levofloxacin, even after a 6-month hospitalization period. Strains FM0300106 and FM0301433 were isolated from case patients 2 and 3 during the sixth week following admission, respectively, and then each patient was colonized for 3 weeks. Eradication of FM0300106 was successfully obtained from case patient 2 by imipenem treatment, while administration of imipenem was continued to prevent pneumonia. Prophylactic antimicrobial therapy was discontinued in case patient 3 because of the lack of pneumonic symptoms, and FM0301433 disappeared after the discontinuation of antimicrobial chemotherapy. All three strains carried the bla(CTX-M-2) gene, and the appearance of colonies in the growth-inhibitory zones around disks of CTX and aztreonam in double-disk synergy tests suggested inducible beta-lactamase production in these A. baumannii strains. The ribotyping investigation suggested that all these strains belong to the same clonal lineage. The plasmids harbored by A. baumannii had the same restriction profile as those harbored by Proteus mirabilis strains previously isolated in a urology ward of the Funabashi Medical Center.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364979      PMCID: PMC516360          DOI: 10.1128/JCM.42.9.3978-3984.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  53 in total

1.  Emergence of carbapenem-hydrolyzing enzymes in Acinetobacter baumannii clinical isolates.

Authors:  G J Da Silva; G J Leitão; L Peixe
Journal:  J Clin Microbiol       Date:  1999-06       Impact factor: 5.948

2.  Cloning, nucleotide sequencing, and analysis of the gene encoding an AmpC beta-lactamase in Acinetobacter baumannii.

Authors:  G Bou; J Martínez-Beltrán
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 3.  Acinetobacter species as nosocomial pathogens.

Authors:  D H Forster; F D Daschner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-02       Impact factor: 3.267

4.  Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome.

Authors:  A Raimondi; F Sisto; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

5.  Cloning and nucleotide sequence analysis of a gene encoding an OXA-derived beta-lactamase in Acinetobacter baumannii.

Authors:  J Vila; M Navia; J Ruiz; C Casals
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii.

Authors:  Felipe Fernández-Cuenca; Luis Martínez-Martínez; Maria Carmen Conejo; Juan A Ayala; Evelio J Perea; Alvaro Pascual
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

7.  Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate.

Authors:  P A Bradford; C E Cherubin; V Idemyor; B A Rasmussen; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam.

Authors:  E S Go; C Urban; J Burns; B Kreiswirth; W Eisner; N Mariano; K Mosinka-Snipas; J J Rahal
Journal:  Lancet       Date:  1994-11-12       Impact factor: 79.321

9.  Bacteriological, clinical and epidemiological characteristics of hospital-acquired Acinetobacter baumannii infection in a teaching hospital.

Authors:  M Ayan; R Durmaz; E Aktas; B Durmaz
Journal:  J Hosp Infect       Date:  2003-05       Impact factor: 3.926

10.  Cloning and sequence of the gene encoding a cefotaxime-hydrolyzing class A beta-lactamase isolated from Escherichia coli.

Authors:  Y Ishii; A Ohno; H Taguchi; S Imajo; M Ishiguro; H Matsuzawa
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more
  24 in total

1.  Experimental prediction of the evolution of ceftazidime resistance in the CTX-M-2 extended-spectrum beta-lactamase.

Authors:  Kerry J Welsh; Miriam Barlow; Fred C Tenover; James W Biddle; J Kamile Rasheed; Leigh Ann Clark; John E McGowan
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Evaluation of four commercially available extended-spectrum beta-lactamase phenotypic confirmation tests.

Authors:  Andrea J Linscott; William J Brown
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

3.  PCR classification of CTX-M-type beta-lactamase genes identified in clinically isolated gram-negative bacilli in Japan.

Authors:  Naohiro Shibata; Hiroshi Kurokawa; Yohei Doi; Tetsuya Yagi; Kunikazu Yamane; Jun-ichi Wachino; Satowa Suzuki; Kouji Kimura; Satoshi Ishikawa; Haru Kato; Yoshiyuki Ozawa; Keigo Shibayama; Kumiko Kai; Toshifumi Konda; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 4.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

5.  Co-production of ESBL and AmpC β-Lactamases in Clinical Isolates of A. baumannii and A. lwoffii in a Tertiary Care Hospital From Northern India.

Authors:  Pooja Singla; Rama Sikka; Antariksh Deeep; Deep Gagneja; Uma Chaudhary
Journal:  J Clin Diagn Res       Date:  2014-04-15

6.  Genetic features of CTX-M-15-producing Acinetobacter baumannii from Haiti.

Authors:  Anaïs Potron; L Silvia Munoz-Price; Patrice Nordmann; Timothy Cleary; Laurent Poirel
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

7.  PER-8, a Novel Extended-Spectrum β-Lactamase PER Variant, from an Acinetobacter baumannii Clinical Isolate in Nepal.

Authors:  Tatsuya Tada; Shovita Shrestha; Kayo Shimada; Hiroshi Ohara; Jeevan B Sherchand; Bharat M Pokhrel; Teruo Kirikae
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

8.  Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.

Authors:  Yukiko Nagano; Noriyuki Nagano; Jun-ichi Wachino; Keiko Ishikawa; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

9.  Phenotypic and molecular characterization of two novel CTX-M enzymes carried by Klebsiella pneumoniae.

Authors:  Jun Cheng; Wei Gao; Jun Yin; Zhen Sun; Ying Ye; Yu-Feng Gao; Xu Li; Jia-Bin Li
Journal:  Mol Biol Rep       Date:  2009-03-18       Impact factor: 2.316

10.  A novel SHV-type beta-lactamase variant (SHV-89) in clinical isolates in China.

Authors:  Jia-Bin Li; Jun Cheng; Qian Wang; Yan Chen; Ying Ye; Xue-Jun Zhang
Journal:  Mol Biol Rep       Date:  2008-06-29       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.